---
schema_version: "secwatch.filing_event.v1"
accession: "0001829126-26-006688"
form_type: "8-K"
ticker: "NTHI"
cik: "0001979414"
company_name: "NEONC TECHNOLOGIES HOLDINGS, INC."
filed_at: "2026-06-18T21:00:18+00:00"
generated_at: "2026-06-18T21:04:34.006390+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# NeOnc Technologies gets UAE IND approval for NEO212 brain cancer drug

## Summary
- Department of Health – Abu Dhabi granted IND status for NEO212, an oral perillyl alcohol-temozolomide conjugate.
- Phase 1 dose-escalation completed; 610 mg selected as recommended Phase 2 dose.
- Early signs of durable disease stabilization seen in recurrent glioblastoma and brain metastases.
- Company also submitted applications for NEO100 programs in UAE; awaiting decisions.
- UAE approval follows U.S. FDA discussions on potential registrational pathway.

## SEC filing metadata
- accession: 0001829126-26-006688
- form_type: 8-K
- ticker: NTHI
- cik: 0001979414
- company_name: NEONC TECHNOLOGIES HOLDINGS, INC.
- filed_at: 2026-06-18T21:00:18+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1979414/000182912626006688/0001829126-26-006688-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1979414/000182912626006688/neonctechnologies_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001829126-26-006688
- JSON: https://secwatch.observer/filing/0001829126-26-006688.json
- Plain text: https://secwatch.observer/filing/0001829126-26-006688.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.